Biogen Inc
BIIB: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$178.00 | Hjzxr | Rldymwwk |
Maintaining Our Biogen FVE Following in Line Q3; Potential Approval of Lecanemab Approaches
On the heels of positive results for Biogen and partner Eisai’s Alzheimer’s disease drug candidate lecanemab, Biogen reported third-quarter results that were in line with our expectations, and we’re maintaining our $330 fair value estimate.